Tag: ziftomenib

KOMZIFTI (ziftomenib) Added to National Comprehensive Cancer Network (NCCN) Guidelines for Acute Myeloid Leukemia (AML)

KOMZIFTI, the first and only once-daily FDA-approved menin inhibitor for R/R NPM1-mutated…

GlobeNews Wire